Parison Amy sold $2K of EDIT
Parison Amy (SVP, Chief Financial Officer) sold 678 shares of Editas Medicine, Inc. (EDIT) at $2.58 on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s planned open-market sale details (shares, price, total value, and post-sale holdings).
Market read
Traders may note insider selling, but the transaction size and 10b5-1 framing suggest limited trading significance absent other catalysts.
What to watch
The article does not provide context on total insider holdings beyond the post-transaction figure, nor does it indicate any concurrent buys or other corporate developments.
Background
The article is a SEC Form 4 insider transaction disclosure for Editas Medicine, Inc.
Ticker impact
Editas Medicine CFO Parison Amy filed a Form 4 open-market sale of 678 shares at $2.58 on 2026-08-03 under a 10b5-1 plan.
Likely minimal price impact; any effect is short-lived unless accompanied by other news.
The filing is a routine 10b5-1 planned sale with small dollar value ($1,749.24) relative to typical market moves, and the article provides no new operational or financial catalyst.
Market effects
No sector read-through; this is a single planned insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerEditas Medicine, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderParison Amy
SVP and Chief Financial Officer who sold shares under a 10b5-1 plan.
